This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bednar, M. M. Articles by Gross, C. E. Search for Related Content PubMed PubMed Citation Articles by Bednar, M. M. Articles by Gross, C. E.

Stroke, Vol 21, 1705-1709, Copyright © 1990 by American Heart Association

ARTICLES

Tissue plasminogen activator reduces brain injury in a rabbit model of thromboembolic stroke

MM Bednar, T McAuliffe, S Raymond and CE Gross
Division of Neurosurgery, University of Vermont, Burlington.

Tissue plasminogen activator is an endogenous fibrin-specific serine protease with potent thrombolytic activity. We investigated the efficacy of tissue plasminogen activator in reducing cerebral infarct size after thromboembolic stroke in a rabbit model. Seventeen rabbits were randomized to receive either tissue plasminogen activator (2.5 mg/kg, n = 6) or vehicle control (n = 11). We controlled mean arterial pressure, hematocrit, and arterial blood gases before and after the intracarotid embolization of an autologous clot. Cerebral blood flow (cm3/100 g/min) (mean +/- SEM) was immediately reduced from 55.2 +/- 7.7 to 8.5 +/- 2.5 in the control group and from 61.8 +/- 14.8 to 10.0 +/- 3.5 in the treated group after embolization. Cerebral blood flow recovered significantly within 60 minutes of thrombolytic therapy and attained a value of 59.6 +/- 10.0 cm3/100 g/min 4 hours after embolization, whereas cerebral blood flow in control animals demonstrated only a minimal recovery to 15.3 +/- 8.9 cm3/100 g/min. Cerebral infarct size (percent of hemisphere) was reduced from 34.4 +/- 5.6% in control animals to 8.8 +/- 5.6% in treated animals (mean +/- SEM, p less than 0.01). These results suggest that tissue plasminogen activator may be efficacious in restoring cerebral blood flow and thus limiting infarct size in acute thromboembolic stroke.

This article has been cited by other articles:

				K. Kirchhof, T. Welzel, S. Zoubaa, C. Lichy, M. Sikinger, H. L. de Ruiz, and K. Sartor New Method of Embolus Preparation for Standardized Embolic Stroke in Rabbits Stroke, September 1, 2002; 33(9): 2329 - 2333. [Abstract] [Full Text] [PDF]

				J. I. Suarez, J. L. Sunshine, R. Tarr, O. Zaidat, W. R. Selman, C. Kernich, and D. M. D. Landis Predictors of Clinical Improvement, Angiographic Recanalization, and Intracranial Hemorrhage After Intra-Arterial Thrombolysis for Acute Ischemic Stroke Stroke, October 1, 1999; 30(10): 2094 - 2100. [Abstract] [Full Text] [PDF]

				M. M. Bednar and C. E. Gross Antiplatelet Therapy in Acute Cerebral Ischemia Stroke, April 1, 1999; 30(4): 887 - 893. [Abstract] [Full Text] [PDF]

				P. Pantano, F. Caramia, L. Bozzao, C. Dieler, and R. von Kummer Delayed Increase in Infarct Volume After Cerebral Ischemia : Correlations with Thrombolytic Treatment and Clinical Outcome Stroke, March 1, 1999; 30(3): 502 - 507. [Abstract] [Full Text] [PDF]

				S. Vanderschueren, I. Van Vlaenderen, and D. Collen Intravenous Thrombolysis With Recombinant Staphylokinase Versus Tissue-Type Plasminogen Activator in a Rabbit Embolic Stroke Model Stroke, September 1, 1997; 28(9): 1783 - 1788. [Abstract] [Full Text]

				N. Heye Microthromboemboli in Acute Infarcts : Analysis of 40 Autopsy Cases Stroke, March 1, 1996; 27(3): 431 - 434. [Abstract] [Full Text]

				G. R. Thomas, H. Thibodeaux, C. J. Errett, M. M. Bednar, C. E. Gross, and W. F. Bennett Intravenous Aspirin Causes a Paradoxical Attenuation of Cerebrovascular Thrombolysis Stroke, June 1, 1995; 26(6): 1039 - 1046. [Abstract] [Full Text]

				R. von Kummer, R. Holle, L. Rosin, M. Forsting, and W. Hacke Does Arterial Recanalization Improve Outcome in Carotid Territory Stroke? Stroke, April 1, 1995; 26(4): 581 - 587. [Abstract] [Full Text]